Harpoon Therapeutics (NASDAQ:HARP – Get Free Report)’s stock had its “neutral” rating reissued by equities research analysts at Citigroup in a research note issued to investors on Monday, Benzinga reports. They currently have a $23.00 target price on the stock, up from their previous target price of $13.00. Citigroup’s target price would indicate a potential upside of 0.31% from the company’s current price.
A number of other research firms have also recently weighed in on HARP. Oppenheimer initiated coverage on Harpoon Therapeutics in a research report on Friday, January 5th. They set an “outperform” rating and a $23.00 price objective on the stock. HC Wainwright downgraded Harpoon Therapeutics from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $12.00 to $23.00 in a research note on Monday, January 8th. Leerink Partnrs downgraded Harpoon Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Finally, TD Cowen reissued a “market perform” rating on shares of Harpoon Therapeutics in a research report on Tuesday, January 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Harpoon Therapeutics has a consensus rating of “Hold” and an average price target of $27.25.
Harpoon Therapeutics Price Performance
HARP remained flat at $22.93 during trading on Monday. The company’s stock had a trading volume of 417,833 shares, compared to its average volume of 1,448,364. The firm’s 50 day simple moving average is $19.07 and its 200 day simple moving average is $11.41. The company has a market capitalization of $388.20 million, a P/E ratio of -2.62 and a beta of 2.12. Harpoon Therapeutics has a twelve month low of $3.11 and a twelve month high of $22.97.
Institutional Investors Weigh In On Harpoon Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HARP. BlackRock Inc. raised its holdings in shares of Harpoon Therapeutics by 5.6% in the 1st quarter. BlackRock Inc. now owns 1,809,686 shares of the company’s stock valued at $8,994,000 after buying an additional 95,355 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Harpoon Therapeutics by 50.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 103,267 shares of the company’s stock valued at $513,000 after purchasing an additional 34,578 shares during the period. Sequoia Financial Advisors LLC purchased a new stake in Harpoon Therapeutics during the 1st quarter valued at approximately $66,000. Vanguard Group Inc. raised its stake in Harpoon Therapeutics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 1,288,202 shares of the company’s stock valued at $6,402,000 after acquiring an additional 34,392 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Harpoon Therapeutics by 309.3% during the 1st quarter. Renaissance Technologies LLC now owns 211,200 shares of the company’s stock worth $1,050,000 after buying an additional 159,600 shares in the last quarter. Hedge funds and other institutional investors own 74.01% of the company’s stock.
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma.